Why do some people age rapidly while others maintain their health well into their 80s and 90s? A new study suggests that maintaining “youthful” organs may be key. Scientists led by Tony Wyss-Coray at ...

Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.

At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

This article discusses the role of receptors and lysosomal dysfunction in APOE variant-related Alzheimer's disease risk.

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Other news from AAIC? Long-term lecanemab dosing in open-label extensions now goes out to three years, and continues to support the idea that the antibody slows disease progression. On cognitive ...

A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential ...

Today the U.S. Food and Drug Administration’s advisory committee gave the nod to donanemab, clearing the way for its marketing approval. All 11 members voted that the antibody was effective for people ...